We previously demonstrated that the risk of enhanced tumor hypoxia in response to the inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2) PTK787/ZK222584 (PTK787) exists, but is minimal when PTK787 is combined with IR [3]. Here, KDR is linked to neoplasm.